Myasthenia Gravis (MG) Treatment Industry Forecast to 2030: A $2.5 Billion Market Dominated by Alexion Pharma, Grifols, Avadel Pharma, Novartis, Pfizer, AbbVie, and Roche [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
The global myasthenia gravis treatment market is expected to reach an estimated $2.5 billion by 2030 with a CAGR of 6.3% from 2024 to 2030. The major drivers for this market are increasing awareness of rare diseases, the introduction of biologics and approval of promising medications, along with the growing use of immunotherapies. The future of the market looks promising with opportunities in the hospital and clinic markets. This study includes a forecast for the global myasthenia gravis treatment by treatment type, end use, and region. Myasthenia Gravis Treatment Market by Treatment Type [Shipment Analysis by Value from 2018 to 2030]: Cholinesterase Inhibitors Chronic Immunomodulators Monoclonal Antibodies Rapid Immunotherapies Thymectomy Others Myasthenia Gravis Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]: Hospitals Clinics Others Myasthenia Gravis Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]: N
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- BIOSECURE bill targets more Chinese companies as biotechs and their customers adapt to defunding [Yahoo! Finance]Yahoo! Finance
- Why This 1 Value Stock Could Be a Great Addition to Your Portfolio [Yahoo! Finance]Yahoo! Finance
- CAR T-Cell Therapy Market to Reach Valuation of USD 22.2 Billion By 2032: Astute Analytica [Yahoo! Finance]Yahoo! Finance
- Cell and gene therapy companies trip at scalability hurdle [Yahoo! Finance]Yahoo! Finance
- Gordian Biotechnology Introduces High-Throughput In Vivo Screening Platform to Discover Therapies and Better Predict Human Outcomes for Age-Related Diseases [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 4/23/24 - Beat
NVS
Sec Filings
- 4/23/24 - Form 6-K
- 2/15/24 - Form S-8
- 2/2/24 - Form SC
- NVS's page on the SEC website